Search results
Results From The WOW.Com Content Network
The Mitsubishi Lancer Evolution, popularly referred to as the 'Evo', [1] is a sports sedan and rally car based on the Lancer that was manufactured by Japanese manufacturer Mitsubishi Motors from 1992 until 2016. There have been ten official versions to date, and the designation of each model is most commonly a Roman numeral.
The Mitsubishi Lancer Evolution X is the tenth and final generation of the Lancer Evolution, a sports sedan produced by Japanese manufacturer Mitsubishi Motors.. By September 2005, Mitsubishi introduced a concept version of the next-gen Evolution at the 39th Tokyo Motor Show named the Concept-X, [1] designed by Omer Halilhodžić at the company's European design centre.
A A Automobile Company (1910–1913) 'Blue & Gold, Red John, model Abbott-Detroit (1909–1918) Moved to Cleveland and renamed to 'Abbott' in 1917. Abeln-Zehr (1911–1912) Renamed to 'Zehr' after departure of S. Abeln in 1912. AC Propulsion (1997–2003) tzero model Apex Motor Car Company (1920–1922) Ace model Acme Motor Car Company (1903–1911) Adams Company (1905–1912) 'Adams-Farwell ...
Mitsubishi Evolution may refer to: Mitsubishi Lancer Evolution; Mitsubishi Pajero Evolution This page was last edited on 11 ...
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
A Mitsubishi Pajero Evolution, driven by Andrew Cowan, finished the 1984 Paris–Alger–Dakar as the third ranked winner in overall class after covering more than 11,000 km. Mitsubishi dominated with multiple first, second and third place podium finishes until their final wins in 2007.
McCulloch Motors Corporation is an American manufacturer of chainsaws and other outdoor power tools.The company was founded in Milwaukee, Wisconsin, in 1943 by Robert Paxton McCulloch as a manufacturer of small two-stroke gasoline engines and introduced its first chainsaw in 1948, the Model 5-49.
Drugs or medicines may be withdrawn from commercial markets because of risks to patients, but also because of commercial reasons (e.g. lack of demand and relatively high production costs).